Page 249 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes

Health Outcome Measures:

donepezil rivastigmine 74.9 74.0 64 54 20.7 21.5 20.8 20.4 50% 48% Primary Outcome Measures: ADAS-Cog (blinded rater); MMSE (un-blinded clinician) Secondary Outcome Measures: Satisfaction/ease of use as measured by questionnaire developed by Pfizer and Eisai (clinician and caregiver satisfaction/ease of use) Timing of assessments: Baseline and weeks 4 and 12 Physicians reported better mean total satisfaction/ease of use with DON than with RIV at 12 weeks (P < 0.0001) Caregivers reported better mean total satisfaction/ease of use with DON tha

• • •

Final Report Update 1 Authors: Wilkinson et al. Year: 2002 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Other germane population qualities: Mean baseline MMSE score • Mean baseline ADAS-Cog • Taking ≥ 1 concomitant med • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs